Further studies have confirmed TMPRSS2:ERG to be a highly-specific PCa biomarker that is present in at least 50% of PCa cases7 and is associated with PCa progression through inducing androgen-regulated ERG overexpression as well as partnering with other oncogenic events such as PTEN loss8. The gene discussed is TMPRSS2; the disease is posterior cortical atrophy.